199 related articles for article (PubMed ID: 17674311)
81. Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Ma CKK; Clancy L; Simms R; Burgess J; Deo S; Blyth E; Micklethwaite KP; Gottlieb DJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):71-77. PubMed ID: 28864137
[TBL] [Abstract][Full Text] [Related]
82. Vaccination against human cytomegalovirus with live virus.
Plotkin SA; Friedman HM; Starr S; Fleisher G
Dev Biol Stand; 1982; 52():373-9. PubMed ID: 6299846
[No Abstract] [Full Text] [Related]
83. Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine.
Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
Birth Defects Orig Artic Ser; 1984; 20(1):271-87. PubMed ID: 6329367
[No Abstract] [Full Text] [Related]
84. Induction of endothelial cell damage by hCMV molecular mimicry.
Lunardi C; Bason C; Corrocher R; Puccetti A
Trends Immunol; 2005 Jan; 26(1):19-24. PubMed ID: 15629405
[TBL] [Abstract][Full Text] [Related]
85. Update on human cytomegalovirus in destructive periodontal disease.
Slots J
Oral Microbiol Immunol; 2004 Aug; 19(4):217-23. PubMed ID: 15209990
[TBL] [Abstract][Full Text] [Related]
86. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial.
Balfour HH; Sachs GW; Welo P; Gehrz RC; Simmons RL; Najarian JS
Birth Defects Orig Artic Ser; 1984; 20(1):289-304. PubMed ID: 6329368
[No Abstract] [Full Text] [Related]
87. Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection.
Varani S; Frascaroli G; Gibellini D; Potena L; Lazzarotto T; Lemoli RM; Magelli C; Söderberg-Naucler C; Landini MP
Transplantation; 2005 Jan; 79(2):219-27. PubMed ID: 15665771
[TBL] [Abstract][Full Text] [Related]
88. Cell-mediated immunity to cytomegalovirus in mice and in renal transplant recipients.
Howard RJ; Balfour HH
Transplant Proc; 1979 Mar; 11(1):75-8. PubMed ID: 222021
[No Abstract] [Full Text] [Related]
89. Live cytomegalovirus vaccination of healthy volunteers: eight-year follow-up studies.
Stern H
Birth Defects Orig Artic Ser; 1984; 20(1):263-9. PubMed ID: 6329366
[No Abstract] [Full Text] [Related]
90. Delayed type hypersensitivity to human cytomegalovirus.
Gupta R; Gonczol E; Manning ML; Starr S; Johnson B; Murphy GF; Plotkin SA
J Med Virol; 1993 Feb; 39(2):109-17. PubMed ID: 8387567
[TBL] [Abstract][Full Text] [Related]
91. Polypeptide-specific antibody response to human cytomegalovirus after infection in bone marrow transplant recipients.
Zaia JA; Forman SJ; Ting YP; Vanderwal-Urbina E; Blume KG
J Infect Dis; 1986 Apr; 153(4):780-7. PubMed ID: 3005437
[TBL] [Abstract][Full Text] [Related]
92. Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.
Nelson CS; Baraniak I; Lilleri D; Reeves MB; Griffiths PD; Permar SR
J Infect Dis; 2020 Mar; 221(Suppl 1):S45-S59. PubMed ID: 32134477
[TBL] [Abstract][Full Text] [Related]
93. Preventing Infection by Human Cytomegalovirus.
Plotkin SA
J Infect Dis; 2020 Mar; 221(Suppl 1):S123-S127. PubMed ID: 32134484
[TBL] [Abstract][Full Text] [Related]
94. Vaccination against Herpes group viruses, in particular, cytomegalovirus.
Plotkin SA
Monogr Paediatr; 1979; 11():58-74. PubMed ID: 226876
[No Abstract] [Full Text] [Related]
95. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.
Plotkin SA; Starr SE; Friedman HM; Gönczöl E; Weibel RE
J Infect Dis; 1989 May; 159(5):860-5. PubMed ID: 2540247
[TBL] [Abstract][Full Text] [Related]
96. Recent clinical isolates of cytomegalovirus suppress human cytomegalovirus-specific human leukocyte antigen-restricted cytotoxic T-lymphocyte activity.
Schrier RD; Oldstone MB
J Virol; 1986 Jul; 59(1):127-31. PubMed ID: 3012111
[TBL] [Abstract][Full Text] [Related]
97. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT.
Ljungman P; Engelhard D; de la Cámara R; Einsele H; Locasciulli A; Martino R; Ribaud P; Ward K; Cordonnier C;
Bone Marrow Transplant; 2005 Apr; 35(8):737-46. PubMed ID: 15750612
[TBL] [Abstract][Full Text] [Related]
98. Could a vaccine against immune-evading cytomegalovirus become a reality?
Emery VC
Expert Rev Vaccines; 2011 Aug; 10(8):1109-11. PubMed ID: 21854303
[No Abstract] [Full Text] [Related]
99. Interactions of cytomegalovirus with the human immune system.
Rook AH
Rev Infect Dis; 1988; 10 Suppl 3():S460-7. PubMed ID: 2847282
[TBL] [Abstract][Full Text] [Related]
100. Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients.
Rook AH; Quinnan GV; Frederick WJ; Manischewitz JF; Kirmani N; Dantzler T; Lee BB; Currier CB
Am J Med; 1984 Mar; 76(3):385-92. PubMed ID: 6322583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
